Category: Addiction Medicine

The Silent Threat: How Excessive Alcohol Consumption Increases Cancer Risk

Many people enjoy a drink without a second thought, but did you know that excessive alcohol consumption can significantly increase your risk of developing several types of cancer? It’s a hidden danger that often goes unnoticed. Here’s a breakdown of the various forms of cancer linked to heavy drinking:

1. Mouth and Throat Cancer (Oral and Pharyngeal)

Alcohol irritates the cells in your mouth and throat, making them more susceptible to carcinogens. Heavy drinkers are at much higher risk of developing cancers in these areas, especially when combined with smoking.

2. Esophageal Cancer

Drinking alcohol can damage the cells lining the esophagus, leading to DNA mutations over time. Certain genetic factors, such as deficiencies in alcohol metabolism, can further increase this risk.

3. Liver Cancer

Your liver is responsible for breaking down alcohol, and chronic drinking leads to inflammation, cirrhosis, and eventually liver cancer. Hepatocellular carcinoma is the most common type of liver cancer linked to alcohol abuse.

4. Breast Cancer

Alcohol affects hormone levels, particularly estrogen, which can contribute to an increased risk of breast cancer. Even moderate drinking can elevate this risk in women.

5. Colon and Rectal Cancer

Excessive alcohol consumption is linked to cancers of the colon and rectum. Alcohol disrupts the way your body processes nutrients, leading to inflammation and other conditions that promote cancer development.

6. Pancreatic Cancer

Chronic alcohol use can inflame the pancreas, increasing the risk of pancreatic cancer. Since this cancer is notoriously difficult to detect early, the connection to alcohol makes prevention even more critical.

Reduce Your Risk

The more alcohol you consume, the higher your risk of developing cancer. While occasional drinking in moderation might not significantly raise your risk, chronic and heavy drinking has been strongly linked to these cancers. To lower your risk:

  • Limit alcohol intake
  • Stay informed about the impact of alcohol on your body
  • Get regular health check-ups, especially if you drink often
0

Locked Out: Why Most Inmates Are Denied Life-Saving Opioid Treatment

The JAMA Network Open article titled “Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails” investigates the availability of medications for opioid use disorder (MOUD) in U.S. jails, such as methadone, buprenorphine, and naltrexone. It highlights that MOUD, which is a critical component in treating opioid use disorder (OUD), is underutilized in correctional facilities, despite its effectiveness in reducing overdose rates, withdrawal symptoms, and recidivism.

Key factors influencing MOUD availability in jails include jail size, regional location, the political landscape, and resources available in the facility. Jails in larger urban areas or those in states with Medicaid expansion are more likely to provide MOUD. Barriers such as stigma, lack of funding, and inadequate healthcare infrastructure also limit access to these medications.

The study emphasizes the importance of expanding access to MOUD in jails to address the opioid epidemic and improve public health outcomes for incarcerated populations as only 44% of jails offer MOUD in the current system. 

0

Psilocybin Outshines Escitalopram: A Breakthrough in Depression Treatment

The article Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialreports findings from an extended observation period on the comparative effects of psilocybin and escitalopram in treating depression. Here are the key points:

Study Design: This was a 6-month follow-up of a Phase 2, double-blind, randomized controlled trial. It compared the effects of psilocybin (a psychedelic compound) and escitalopram (a common SSRI) on depression symptoms in patients with moderate-to-severe major depressive disorder (MDD).

Participants: Patients with moderate-to-severe MDD were randomly assigned to either psilocybin or escitalopram groups. Both treatments were administered in a controlled clinical setting

Primary Outcome: Depression symptom severity was measured using the QIDS-SR-16 (Quick Inventory of Depressive Symptomatology–Self-Report) scale at various time points, including baseline, during the treatment phase, and at the 6-month follow-up.

Results:

Both groups showed improvement in depression symptoms, but the psilocybin group had a greater reduction in symptoms compared to the escitalopram group.

The effects of psilocybin were found to be more rapid and sustained over the 6-month period.

Remission and Response Rates: A higher proportion of patients in the psilocybin group achieved remission and clinically significant response compared to those in the escitalopram group.

Safety and Side Effects: Both treatments were generally well-tolerated. However, psilocybin was associated with transient, mild-to-moderate side effects, mostly during the acute phase of treatment (e.g., perceptual disturbances).

Conclusion: Psilocybin demonstrated more pronounced and longer-lasting antidepressant effects compared to escitalopram at the 6-month follow-up. This suggests that psilocybin could be a viable alternative treatment for moderate-to-severe depression, but further research is necessary to confirm long-term safety and efficacy.

0

Want to Live Longer with a Serious Mental Health Condition? Say No to Alcohol, Drugs, and Smoking!

The article “Major Psychiatric Disorders, Substance Use Behaviors, and Longevity” explores the complex relationships between psychiatric disorders, substance use, and life expectancy. The authors examine how conditions like schizophrenia, bipolar disorder, and major depression affect longevity, often leading to reduced lifespans. This is largely due to increased risk factors, such as poor physical health, unhealthy lifestyles, and increased rates of suicide.

Substance use behaviors, including alcohol, tobacco, and drug use, often co-occur with psychiatric disorders, compounding the negative effects on longevity. The article emphasizes the need for better integration of mental health and substance use treatment into healthcare systems. It also advocates for targeted interventions to reduce mortality rates, improve the quality of life, and enhance access to comprehensive care for individuals with psychiatric disorders.

Link to the article: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2820199

0

U.S. Overdose Deaths Hit Historic Low: A Turning Point in the Opioid Crisis

A recent NPR exclusive reveals a significant and unexpected decline in U.S. overdose deaths, marking the first drop in decades. Data from the Centers for Disease Control and Prevention (CDC) shows a nationwide reduction of roughly 10.6% in overdose deaths. Some states with rapid data collection have seen declines as high as 20-30%, suggesting the possibility of saving up to 20,000 lives annually.

This turnaround follows years of increasing fatalities, largely driven by fentanyl and other synthetic opioids. Experts credit the broader availability of life-saving treatments, such as naloxone, and improvements in support systems for people at risk of overdosing. While the overall number of overdose deaths remains high, many in the public health community are cautiously optimistic, believing the worst of the crisis might be over for now

0

Rethinking the Concept of Addiction: Beyond the Brain Disease Model

When it comes to treating addiction, the prevailing idea is that it’s simply a chronic brain disease. But in reality, few experts fully subscribe to this view in isolation. We understand that not everyone who uses drugs, alcohol, or gambles ends up with a life-destroying addiction. Many individuals manage to engage with substances or behaviors without it overtaking their lives—they maintain jobs, care for their families, and function in society. This suggests that addiction is much more than a biological condition; it’s an intricate interplay of biology, social influences, environmental factors, and personal choices.

It’s worth pausing to consider what labeling addiction as a chronic disease implies. On one hand, it suggests that even if you strive for change, addiction remains a lingering presence—one that can pull you back into destructive patterns at any moment. This can foster a disheartening and pessimistic outlook, as it positions addiction as an inescapable burden. The concept of a chronic disease also reinforces the idea that ongoing, lifelong treatment is necessary, often with medications like buprenorphine, which may be prescribed for years, or even indefinitely, to prevent relapse.

While I absolutely recognize the biological underpinnings of addiction and the life-saving role medications like buprenorphine play, we must look beyond just biology to truly understand and address addiction. The motivations behind substance use and the social contexts in which it occurs are equally important. Humanity’s long history of seeking altered states of consciousness suggests that drug use is often a response to emotional pain or difficult circumstances. People frequently use substances as an escape, and understanding these personal and social factors is key to effective treatment.

At its core, successful addiction therapy must focus on uncovering the reasons behind substance use and helping individuals develop healthier coping strategies. Treatment that focuses solely on the biological side—without considering the psychological and social aspects—often falls short. It’s critical to provide not just medical interventions but also hope and optimism, which are fundamental to any healing process. Addiction may not be a simple choice, but it certainly involves choices, and it emerges from a complex web of circumstances in a person’s life.

In the end, we should avoid oversimplifying addiction as merely a chronic brain disease. True treatment requires a holistic approach, considering all the elements—biological, social, environmental, and personal—that create the conditions for addiction to thrive. Only then can we offer meaningful, lasting solutions for those struggling with addiction.

Link to the article:

0

Unproven Lifeline? Nalmefene’s Missing Tests in the Synthetic Opioid Era

It seems we may have spoken too soon about the nalmefene hydrochloride auto-injector for opioid overdoses. It turns out no one really knows if there’s enough clinical data to support its use in the current landscape of high-potency synthetic opioids. That’s a pretty big oversight for a company releasing an opioid reversal agent. There are also concerns about severe and prolonged withdrawal due to its long half-life of 10.8 hours.

And, in a twist of irony, this drug is produced by the same company that devastated countless lives with OxyContin—Purdue Pharma. You have to hand it to them; they really have no shame. While I’m always eager for new tools to save lives, it’s shocking that they didn’t properly test the medication against the very synthetic opioids flooding the market. I guess we’ll soon find out if this new option will be helpful in emergency situations.

0

Hands Off the Hand Sanitizer: It’s Not a Cocktail

Have you ever noticed that hand sanitizer is sometimes locked up in certain areas of the hospital? The reason for this is that individuals with severe alcohol use disorder may attempt to drink it. One of the highest blood alcohol levels (BAL) I’ve ever encountered came from a patient who found an unlocked dispenser, opened it, and consumed an entire bottle of sanitizer. Their BAL was an alarming 600 when we tested them. This highlights the dangers and societal impact of risky alcohol consumption—something I’ve witnessed firsthand in the inpatient setting.

https://www.medscape.com/viewarticle/hand-sanitizers-and-alcohol-abuse-dangerous-cocktail-2024a1000f7o?ecd=WNL_trdalrt_pos1_240821_etid6766231&uac=267049CZ&impID=6766231

0

Should Marijuana be Reclassified? 

The potential reclassification of marijuana to Schedule III under the Controlled Substances Act would represent a significant shift in how the United States views and regulates the drug. Currently listed as a Schedule I substance, alongside drugs like heroin and LSD, marijuana is classified as having no accepted medical use and a high potential for abuse according to federal law. However, the mounting evidence of its medicinal benefits and changing attitudes toward its use have sparked discussions about revisiting its scheduling.

Moving marijuana to Schedule III would acknowledge its recognized medical applications while still imposing regulatory controls. Drugs in this category, such as certain opioids like codeine, have a moderate to low potential for physical and psychological dependence and are accepted for medical use with restrictions. This reclassification could facilitate further research into its therapeutic properties and enable easier access for patients who could benefit from its use.

However, the reclassification process is complex and involves various legal, political, and scientific considerations. Advocates argue that placing marijuana in Schedule III or lower would align its scheduling with scientific evidence and public opinion, potentially reducing stigma and barriers to research. Critics express concerns about the potential for increased recreational use and addiction, as well as the regulatory challenges of managing a substance with psychoactive properties.

Any decision to reschedule marijuana would require careful deliberation, weighing the potential benefits against the risks and ensuring that public health and safety remain paramount. 

0

Alcohol: The Socially Acceptable Drink That Could Be Killing You

While alcohol is widely accepted in social settings and deeply embedded in many cultures, it’s important to recognize that its social acceptance does not make it harmless. In fact, alcohol has caused far more harm than many illegal substances that are often perceived as more dangerous.

Alcohol is linked to numerous health problems, including liver disease, heart issues, and various forms of cancer. It’s also a leading contributor to accidents, violence, and fatalities, with drunk driving being one of the most deadly consequences. Beyond physical health, alcohol abuse can devastate relationships, contribute to domestic violence, and exacerbate mental health conditions like depression and anxiety.

Alcohol’s normalized presence in society often downplays the risks of dependency and addiction. Many people who drink don’t realize how easy it can be to develop problematic drinking, which can lead to a host of long-term issues, both physically and emotionally.

Despite its legal status and social acceptance, alcohol has proven to be one of the most harmful substances in terms of both individual and societal impact. Recognizing the risks and encouraging more mindful consumption can help reduce the extensive harm caused by this seemingly benign substance.

Link:

https://www.washingtonpost.com/wellness/2024/08/19/alcohol-drinking-deaths-worldwide

0

Powered by WordPress.com.

Up ↑